Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Man's best friend may soon visit the ICU: feasibility study launches

NCT ID NCT07159568

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether it's practical and safe for ICU patients to have short visits from their own pet dogs. Researchers will test this with 21 adult patients in three ICUs in France. The dog can stay for up to 15 minutes, and staff will check for any problems. The goal is to see if such visits can become a regular option to help patients feel better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pet dog visit
What this could lead to
If successful, this could pave the way for pet visits in ICUs, potentially improving patient well-being and comfort during a stressful hospital stay.
What could go wrong
This is a very small feasibility study with only 21 participants, so results may not apply widely. There are risks like infection or accidental dislodgement of medical equipment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 21 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged 18 years or older, * Admitted to one of the participating ICUs at Clermont-Ferrand University Hospital (Estaing Adult ICU, Montpied Medical-Surgical ICU, or Montpied Neuro-ICU) with an expected ICU stay of 48 hours or more, * Owner of a companion dog, with family members or relatives able to bring the dog to the ICU. Exclusion Criteria: Patient-related exclusion criteria: * Refusal by the patient or by their family/relatives to participate, * Lack of affiliation with the French national health insurance system (Sécurité Sociale), * Patient deprived of liberty or under legal protection (guardianship, curatorship, or judicial safeguard), * Pregnant or breastfeeding patient, * Agitated patient, defined as a Richmond Agitation-Sedation Scale (RASS) score \> 0 (monitored every four hours according to current standard practice), * Patient with immunosuppression, defined as: blood neutrophil count \< 0.5 G/L, ongoing or recent (within the past month) treatment for solid or hematologic cancer (e.g., chemotherapy, radiotherapy, cell therapy), or receiving immunosuppressive drugs (including organ transplant recipients or corticosteroid therapy for more than two weeks), * Patient with known colonization by multidrug-resistant bacteria (as routinely assessed upon ICU admission and weekly thereafter), * Patient with one or more open wounds or injuries that cannot be covered with a dressing. Dog-related exclusion criteria: * Dog belonging to category 1 or 2 breeds considered dangerous under current French regulations, * Dog that never leaves the home environment, * Dog with an incomplete vaccination status, * Dog with a known transmissible disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dog therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.